DD210843A5 - Verfahren zur herstellung eines arzneimittels zur behandlung von neoplasma-erkrankungen - Google Patents
Verfahren zur herstellung eines arzneimittels zur behandlung von neoplasma-erkrankungen Download PDFInfo
- Publication number
- DD210843A5 DD210843A5 DD83252009A DD25200983A DD210843A5 DD 210843 A5 DD210843 A5 DD 210843A5 DD 83252009 A DD83252009 A DD 83252009A DD 25200983 A DD25200983 A DD 25200983A DD 210843 A5 DD210843 A5 DD 210843A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- herba
- treatment
- infusion
- diseases
- medicament
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 title claims description 13
- 201000010099 disease Diseases 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000001802 infusion Methods 0.000 claims abstract description 12
- 241000196324 Embryophyta Species 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019441 ethanol Nutrition 0.000 claims abstract description 6
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 229960000907 methylthioninium chloride Drugs 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- ZVNPWFOVUDMGRP-UHFFFAOYSA-N 4-methylaminophenol sulfate Chemical compound OS(O)(=O)=O.CNC1=CC=C(O)C=C1.CNC1=CC=C(O)C=C1 ZVNPWFOVUDMGRP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 241000581692 Potentilla reptans Species 0.000 claims abstract description 4
- 238000000605 extraction Methods 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 241000219823 Medicago Species 0.000 claims abstract description 3
- 230000002195 synergetic effect Effects 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 4
- 241000693827 Helleborus niger Species 0.000 claims description 3
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 3
- 239000002775 capsule Substances 0.000 abstract description 16
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 229910002007 uranyl nitrate Inorganic materials 0.000 abstract description 4
- 208000035269 cancer or benign tumor Diseases 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 239000012530 fluid Substances 0.000 abstract description 2
- 239000001828 Gelatine Substances 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 238000002386 leaching Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 13
- 229940098465 tincture Drugs 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000021152 breakfast Nutrition 0.000 description 3
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 3
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000527994 Cyclotella gamma Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000010624 Medicago sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000012896 Peritoneal disease Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 201000006812 malignant histiocytosis Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/50—Fumariaceae (Fumitory family), e.g. bleeding heart
- A61K36/505—Corydalis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RO82107893A RO81783A3 (ro) | 1982-06-16 | 1982-06-16 | Medicament pentru tratamentul maladiei neoplazice |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD210843A5 true DD210843A5 (de) | 1984-06-27 |
Family
ID=20111710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD83252009A DD210843A5 (de) | 1982-06-16 | 1983-06-14 | Verfahren zur herstellung eines arzneimittels zur behandlung von neoplasma-erkrankungen |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0111529B1 (ro) |
| CA (1) | CA1203167A (ro) |
| DD (1) | DD210843A5 (ro) |
| DE (1) | DE3366025D1 (ro) |
| IL (1) | IL68896A0 (ro) |
| IT (1) | IT1161934B (ro) |
| RO (1) | RO81783A3 (ro) |
| WO (1) | WO1984000005A1 (ro) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3015481B1 (fr) * | 2013-12-20 | 2016-08-12 | Etat Francais Represente Par Le Delegue General Pour L'armement | Utilisation de composes de diaminophenothiazinium en tant qu'agents de prevention, reduction ou suppression d'une radiotoxicite |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2244468A1 (en) * | 1973-07-31 | 1975-04-18 | Passwater Richard | Anticarcinogenic food supplements - contg antioxidants and S-contg amino acids |
-
1982
- 1982-06-16 RO RO82107893A patent/RO81783A3/ro unknown
-
1983
- 1983-05-26 EP EP83901948A patent/EP0111529B1/en not_active Expired
- 1983-05-26 DE DE8383901948T patent/DE3366025D1/de not_active Expired
- 1983-05-26 WO PCT/RO1983/000001 patent/WO1984000005A1/fr not_active Ceased
- 1983-06-06 IL IL68896A patent/IL68896A0/xx unknown
- 1983-06-14 IT IT21614/83A patent/IT1161934B/it active
- 1983-06-14 DD DD83252009A patent/DD210843A5/de unknown
- 1983-06-15 CA CA000430434A patent/CA1203167A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IT1161934B (it) | 1987-03-18 |
| IL68896A0 (en) | 1983-10-31 |
| DE3366025D1 (en) | 1986-10-16 |
| CA1203167A (en) | 1986-04-15 |
| WO1984000005A1 (fr) | 1984-01-05 |
| RO81783B1 (ro) | 1984-03-08 |
| EP0111529B1 (en) | 1986-09-10 |
| RO81783A3 (ro) | 1984-07-17 |
| EP0111529A1 (en) | 1984-06-27 |
| IT8321614A0 (it) | 1983-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0857064B1 (de) | Stabilisierte schilddrüsenhormonhaltige arzneimittel | |
| DE3328262A1 (de) | Arzneimittelzubereitung zur besserung von krebssymptomen | |
| DE1902227A1 (de) | Arzneimittel zur psychotherapeutischen Anwendung und Verfahren zu seiner Herstellung | |
| DE3022281C2 (de) | Von Alkaloiden befreiter wäßriger Extrakt aus Aconitwurzeln und diesen Extrakt als Wirkstoff enthaltende pharmazeutische Zusammensetzung | |
| EP0435913A1 (de) | Brausetablette. | |
| DE68906765T2 (de) | Zusammensetzung mit einem extrakt,das durch extraktion mit einem wasserhaltigen organischen loesungsmittel erhalten wurde und verfahren zu seiner herstellung. | |
| DE10235465A1 (de) | Neue chinesische Kräuterzusammensetzung zur Verbesserung der Blutzirkulation sowie Verfahren zum Herstellen derselben | |
| DE2434849C2 (de) | Herzstärkende Dosierungseinheit mit Gelatinekapsel | |
| DE2416216C2 (de) | Oral verabreichbares pharmazeutisches Gemisch | |
| DE2126533A1 (de) | Verfahren zur Herstellung pharma zeutischer Zubereitungen | |
| DD210843A5 (de) | Verfahren zur herstellung eines arzneimittels zur behandlung von neoplasma-erkrankungen | |
| DE3818022C2 (de) | Weichgelatinekapsel | |
| DE19603788B4 (de) | Wirkstoffextrakt aus Teufelskrallenwurzel, diesen enthaltendes human- oder veterinärmedizinisches Präparat, Verfahren zur Herstellung eines hochkonzentrierten Extraktes aus Radix Harpagophyti oder Herba und Radix Scrophularia sowie dessen Verwendung | |
| DE69533742T2 (de) | Verwendung von Prolin und/oder Derivaten als Mittel gegen Hepatitis | |
| DE3225056C2 (de) | Verwendung des zerkleinerten Samens des Bockshornklees (Trigonella foenum-graecum) als Wirkstoff zur Bekämpfung toxischer Leberschädigung und/oder zur Verbesserung der Leberfunktion | |
| DE2518509C3 (de) | Pharmazeutisches Mittel für Antitumoraktivität, enthaltend Abrin | |
| DE69526111T2 (de) | Zusammensetzung zur behandlung von endometriose, welche ein salz eines edelmetalles und mel cum sale enthält | |
| DE10238161A1 (de) | Mineralstoff-Ampulle für die mucosale und topische Wirkstoffapplikation | |
| DE2011499A1 (de) | Arzneimittel aus Germaniumsäure und Cystein und Verfahren zu seiner Herstellung | |
| DE2635293A1 (de) | Salzgemisch, insbesondere leicht assimilierbares arzneimittelgemisch mit erhoehter loeslichkeit, enthaltend kalziumsalze und/oder magnesiumsalze | |
| DE102024107455A1 (de) | Leber-schützende zusammensetzung | |
| DE2015877A1 (de) | Arzneimittel | |
| DE651597C (de) | Verfahren zur Darstellung haltbarer Hormonpraeparate | |
| DE3234366A1 (de) | Arzneimittel, insbesondere zur krebstherapie | |
| DE2159322C2 (de) | Pharmazeutische Zubereitung für die Lithium-Therapie |